8.42
-0.09(-1.06%)
Currency In USD
| Previous Close | 8.51 |
| Open | 8.52 |
| Day High | 8.6 |
| Day Low | 8.07 |
| 52-Week High | 9.27 |
| 52-Week Low | 4.35 |
| Volume | 1.53M |
| Average Volume | 1.74M |
| Market Cap | 456.78M |
| PE | -8.24 |
| EPS | -1.01 |
| Moving Average 50 Days | 6.59 |
| Moving Average 200 Days | 5.72 |
| Change | -0.19 |
Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
GlobeNewswire Inc.
Mar 09, 2026 12:05 PM GMT
NEEDHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cance
Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston
GlobeNewswire Inc.
Feb 24, 2026 1:05 PM GMT
NEEDHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer
Candel Therapeutics Announces Proposed $100 Million Public Offering
GlobeNewswire Inc.
Feb 19, 2026 9:05 PM GMT
NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer